E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

E.U. paediatric MOG consortium; Thaís Armangue; Marco Capobianco; Aliénor de Chalus; Giorgi Laetitia; Kumaran Deiva; Arlette L. Bruijstens; Rinze F. Neuteboom

doi:10.1016/j.ejpn.2020.11.001

E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

E.U. paediatric MOG consortium
, Thaís Armangue^*
, Marco Capobianco
, Aliénor de Chalus
, Giorgi Laetitia
, Kumaran Deiva
, Arlette L. Bruijstens
, Rinze F. Neuteboom

^*Corresponding author for this work

Neurology

University of Barcelona
Azienda Ospedaliera S. Luigi Gonzaga
Hôpital Bicêtre
European Reference Network - RITA

Research output: Contribution to journal › Review article › Academic › peer-review

31 Citations (Scopus)

Abstract

A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).

Original language	English
Pages (from-to)	22-31
Number of pages	10
Journal	European Journal of Paediatric Neurology
Volume	29
DOIs	https://doi.org/10.1016/j.ejpn.2020.11.001
Publication status	Published - Nov 2020

Bibliographical note

Funding Information:
This study was supported in part by the Marato TV3 Foundation ( 20141830 ) and Torrons Vicens Foundation ( PFNR0144 to TA).

Publisher Copyright:
© 2020 European Paediatric Neurology Society

Access to Document

10.1016/j.ejpn.2020.11.001

Cite this

E.U. paediatric MOG consortium, Armangue, T., Capobianco, M., de Chalus, A., Laetitia, G., Deiva, K., Bruijstens, A. L., & Neuteboom, R. F. (2020). E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 29, 22-31. https://doi.org/10.1016/j.ejpn.2020.11.001

@article{8ccf0654ed8245488508fadb2e09e182,

title = "E.U. paediatric MOG consortium consensus: Part 3 {\textendash} Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders",

abstract = "A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).",

author = "\{E.U. paediatric MOG consortium\} and Tha{\'i}s Armangue and Marco Capobianco and \{de Chalus\}, Ali{\'e}nor and Giorgi Laetitia and Kumaran Deiva and Bruijstens, \{Arlette L.\} and Wendel, \{Eva Maria\} and Christian Lechner and Frederik Bartels and Carsten Finke and Markus Breu and Lorraine Flet-Berliac and Catherine Adamsbaum and Yael Hacohen and Cheryl Hemingway and Evangeline Wassmer and Ming Lim and Matthias Baumann and Ronny Wickstr{\"o}m and Kevin Rostasy and Neuteboom, \{Rinze F.\}",

note = "Funding Information: This study was supported in part by the Marato TV3 Foundation ( 20141830 ) and Torrons Vicens Foundation ( PFNR0144 to TA). Publisher Copyright: {\textcopyright} 2020 European Paediatric Neurology Society",

year = "2020",

month = nov,

doi = "10.1016/j.ejpn.2020.11.001",

language = "English",

volume = "29",

pages = "22--31",

journal = "European Journal of Paediatric Neurology",

issn = "1090-3798",

}

E.U. paediatric MOG consortium, Armangue, T, Capobianco, M, de Chalus, A, Laetitia, G, Deiva, K, Bruijstens, AL & Neuteboom, RF 2020, 'E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders', European Journal of Paediatric Neurology, vol. 29, pp. 22-31. https://doi.org/10.1016/j.ejpn.2020.11.001

E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. / E.U. paediatric MOG consortium; Armangue, Thaís; Capobianco, Marco et al.
In: European Journal of Paediatric Neurology, Vol. 29, 11.2020, p. 22-31.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - E.U. paediatric MOG consortium consensus

T2 - Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

AU - E.U. paediatric MOG consortium

AU - Armangue, Thaís

AU - Capobianco, Marco

AU - de Chalus, Aliénor

AU - Laetitia, Giorgi

AU - Deiva, Kumaran

AU - Bruijstens, Arlette L.

AU - Wendel, Eva Maria

AU - Lechner, Christian

AU - Bartels, Frederik

AU - Finke, Carsten

AU - Breu, Markus

AU - Flet-Berliac, Lorraine

AU - Adamsbaum, Catherine

AU - Hacohen, Yael

AU - Hemingway, Cheryl

AU - Wassmer, Evangeline

AU - Lim, Ming

AU - Baumann, Matthias

AU - Wickström, Ronny

AU - Rostasy, Kevin

AU - Neuteboom, Rinze F.

N1 - Funding Information: This study was supported in part by the Marato TV3 Foundation ( 20141830 ) and Torrons Vicens Foundation ( PFNR0144 to TA). Publisher Copyright: © 2020 European Paediatric Neurology Society

PY - 2020/11

Y1 - 2020/11

N2 - A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).

AB - A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).

UR - https://www.scopus.com/pages/publications/85096091493

U2 - 10.1016/j.ejpn.2020.11.001

DO - 10.1016/j.ejpn.2020.11.001

M3 - Review article

C2 - 33191096

AN - SCOPUS:85096091493

SN - 1090-3798

VL - 29

SP - 22

EP - 31

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

ER -

E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this